CapsoVision, Inc. (NASDAQ:CV – Get Free Report)’s share price dropped 1.4% during mid-day trading on Thursday . The stock traded as low as $6.91 and last traded at $6.99. Approximately 120,993 shares traded hands during trading, a decline of 5% from the average session volume of 127,416 shares. The stock had previously closed at $7.09.
Analyst Ratings Changes
Separately, Benchmark reduced their target price on shares of CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating on the stock in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.
Get Our Latest Stock Report on CV
CapsoVision Price Performance
CapsoVision (NASDAQ:CV – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share for the quarter. The company had revenue of $2.79 million during the quarter.
Institutional Investors Weigh In On CapsoVision
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CV. Deutsche Bank AG acquired a new position in shares of CapsoVision during the fourth quarter worth approximately $47,000. Wells Fargo & Company MN increased its holdings in shares of CapsoVision by 66.4% in the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after purchasing an additional 2,508 shares in the last quarter. Virtu Financial LLC bought a new position in CapsoVision in the 4th quarter worth approximately $128,000. Millennium Management LLC bought a new position in CapsoVision in the 4th quarter worth approximately $163,000. Finally, Bank of America Corp DE lifted its holdings in CapsoVision by 528.9% during the 1st quarter. Bank of America Corp DE now owns 22,238 shares of the company’s stock worth $162,000 after buying an additional 18,702 shares in the last quarter.
About CapsoVision
CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.
In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.
Featured Stories
- Five stocks we like better than CapsoVision
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for CapsoVision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CapsoVision and related companies with MarketBeat.com's FREE daily email newsletter.
